Cell, Gene And Specialty Drug Costs Intensify For Health Plans

Why It Matters

Specialty and gene‑therapy pricing threatens payer budgets and could reshape benefit design, forcing the industry to innovate cost‑containment approaches.

Key Takeaways

• 43% of plans prioritize specialty drug cost control
• Specialty drugs exceed 60% of employer drug spend
• 85% of plans view cell/gene therapies as major challenge
• Only 9% use oncology site‑of‑care programs, 60% willing

Pulse Analysis

The specialty drug market has become the dominant cost driver for U.S. health plans, eclipsing traditional prescription categories. According to PSG’s 2026 trends report, more than half of prescription spend now comes from high‑priced biologics, and employer‑sponsored plans see these drugs accounting for 60% or more of their total drug budgets. This shift is fueled by breakthrough therapies such as GLP‑1 weight‑loss agents, which have rapidly gained market share, and by a pipeline flooded with cell and gene treatments that promise curative outcomes but carry price tags in the mid‑hundreds of thousands to millions of dollars.

Cell and gene therapies represent the next frontier of cost pressure. PSG cites a $475,000 price for an acute lymphoblastic leukemia therapy and a $3.5 million price for a hemophilia B cure, figures that exceed many health plans’ annual budgets for entire therapeutic classes. The uncertainty surrounding patient uptake, long‑term efficacy, and reimbursement pathways makes forecasting difficult, leaving payers wary of committing resources. Moreover, traditional rebate‑centric contracts provide limited relief for these one‑time, high‑value treatments, prompting a reassessment of risk‑sharing models and the need for outcome‑based agreements.

In response, payers are exploring more integrated benefit designs. While only 9% currently employ site‑of‑care programs to shift oncology infusions from costly hospital settings to physician offices or home, nearly 60% express strong interest, indicating a potential lever for cost reduction. Broader strategies include tighter formulary controls, value‑based contracts, and enhanced data analytics to predict therapy adoption. As specialty and gene‑therapy expenditures continue to climb, the industry’s ability to balance innovation with affordability will determine the sustainability of employer and health‑plan benefit structures.